

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

**DELAY IN PUBLICATION OF THE ANNUAL RESULTS
OF THE GROUP FOR THE YEAR ENDED 30 JUNE 2024
AND
SUSPENSION OF TRADING**

This announcement is made by Wai Chun Bio-Technology Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited Listing Rules (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

DELAY IN PUBLICATION OF ANNUAL RESULTS

Pursuant to Rules 13.49(1) and 13.46(2)(a) of the Listing Rules, Company is required to publish its preliminary results in respect of the financial year ended 30 June 2024 (the “**Annual Results**”) no later than 30 September 2024, and to send the annual report for the same financial year (the “**Annual Report**”) to its shareholders (the “**Shareholders**”) on or before 31 October 2024.

The board (the “**Board**”) of directors (the “**Directors**”) hereby announces that will be a delay in the release of the Annual Results as the auditor of the Company requires more time to assess certain areas, including several outstanding external audit confirmation letters and the first year and late engagement of the auditor in respect of the Annual Results. As such, the Company is unable to publish the Annual Results by 30 September 2024. Despatch of the Annual Report may also be delayed as a result.

Save for the aforesaid reasons, there is no other reason or inside information which lead to the delay in publication of the Annual Results.

SUSPENSION OF TRADING

As the Company cannot publish the preliminary results announcement for the year ended 30 June 2024 by 30 September 2024, application has been made to The Stock Exchange of Hong Kong Limited for suspension of trading of the shares of the Company with effect from 9:00 a.m. on 2 October 2024.

By order of the Board
Wai Chun Bio-Technology Limited
LAM Ka Chun
Executive Director

Hong Kong, 30 September 2024

As at the date of this announcement, the Board consists of one executive Director, namely Mr. Lam Ka Chun and three independent non-executive Directors, namely Mr. Wang Bo, Mr. He Tao and Mr. Kung Ying Tung.